

IN THE SPECIFICATION:

On page 4 please delete paragraph 4 and replace with the following:

Cardiovascular disorders are, for example, atherosclerosis, restenosis after vessel injury or revascularisation treatment, angioplasty (neointima formation, smooth muscle cell migration and proliferation), myocardial infarction or heart failure.

On page 5 please delete paragraph 7 and replace with the following:

Phosphoramidon;

CGS-31447: 1-[[[(1S)-2-[1,1'-biphenyl]-4-yl-1-(1H-tetrazol-5-yl)ethyl]amino]-3-(1-naphthyl)propylphosphonic acid;

CGS-34043: {[(1S)-2-dibenzo[b,d]furan-3-yl-1-(1H-tetrazol-5-yl)ethyl]amino}methylphosphonic acid;

CGS-35066: (2S)-3-dibenzo[b,d]furan-3-yl-2-[(phosphonomethyl)amino] propanoic acid;

CGS-35339: (2S)-3-dibenzo[b,d]furan-3-yl-2-[[[(diphenoxyphosphoryl)methyl]amino]propanoic acid;

WS-79089A: 1,6,9,14-tetrahydroxy-3-(2-hydroxypropyl)-7-methoxy-8,13-dioxo-5,6,8,13-tetrahydrobenzo[a]naphthacene-2-carboxylic acid; WS-75624A: (6-[2-(6-hydroxyheptyl)-1,3-thiazol-4-yl]-4,5-dimethoxy-2-pyridinecarboxylic acid);

PD-069185: N-(1-ethyl-3-piperidinyl)-6-iodo-2-(trichloromethyl)-4-quinazolinamine; SCH-

54470: N-(1-(Hydroxy(1(R)-(N-alpha-(methylsulfonyl)-L-lysylamino)-2-phenylethyl)phosphinylmethyl)cyclopentylcarbonyl)-L-tryptophan dilithium salt; RU-69296:

(2S)-2-[[2-(3-bromobenzyl)-3-sulfanylpropanoyl]amino]-3-(1H-indol-3-yl)propanoic acid;

RU-69739: (2S)-2-[[2-(4-bromobenzyl)-3-sulfanylpropanoyl]amino]-3-(1H-indol-3-

ABB10010P0750US

yl)propanoic acid; KC-12792-2-AB; SLV-306: ((3S,2'R)-3-(1-(2'-(Ethoxycarbonyl)-4'-phenyl-butyl)-cyclopentan-1-carbonylamino)-2,3,4,5-tetrahydro-2-oxo-1H-benzapin-1-acetic acid; FR-901533;